Hepatitis E

• Literatur

• 1 Wedemeyer H, Pischke S, Manns MP. Pathogenesis and treatment of hepatitis E virus infection. Gastroenterology 2012; 142: 1388-1397
• 2 Wichmann O, Schimanski S, Koch J et al. Phylogenetic and case-control study on hepatitis E virus infection in Germany. J Infect Dis 2008; 198: 1732-1741
• 3 Pischke S, Hardtke S, Bode U et al. Ribavirin treatment of acute and chronic hepatitis E: a single center experience. Liver Int 2013; 33: 722-726
• 4 Kamar N, Izopet J, Tripon S et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med 2014; 370: 1111-1120
• 5 Debing Y, Neyts J. Antiviral strategies for hepatitis E virus. Antiviral Res 2014; 102: 106-118
• 6 Feng Z, Lemon SM. Peek-a-boo: membrane hijacking and the pathogenesis of viral hepatitis. Trends Microbiol 2014; 22: 59-64
• 7 Okamoto H. Genetic variability and evolution of hepatitis E virus. Virus Res 2007; 127: 216-228
• 8 Caron M, Enouf V, Than SC et al. Identification of genotype 1 hepatitis E virus in samples from swine in Cambodia. J Clin Microbiol 2006; 44: 3440-3442
• 9 Teshale EH, Grytdal SP, Howard C et al. Evidence of person-to-person transmission of hepatitis E virus during a large outbreak in Northern Uganda. Clin Infect Dis 2011; 50: 1006-1010
• 10 Krumbholz A, Mohn U, Lange J et al. Prevalence of hepatitis E virus-specific antibodies in humans with occupational exposure to pigs. Med Microbiol Immunol 2012; 201: 239-244
• 11 Baylis SA, Koc O, Nick S et al. Widespread distribution of hepatitis E virus in plasma fractionation pools. Vox Sang 2011; 102: 182-183
• 12 Schlosser B, Stein A, Neuhaus R et al. Liver transplant from a donor with occult HEV infection induced chronic hepatitis and cirrhosis in the recipient. J Hepatol 2012; 56: 500-502
• 13 Bendall R, Ellis V, Ijaz S et al. A comparison of two commercially available anti-HEV IgG kits and a re-evaluation of anti-HEV IgG seroprevalence data in developed countries. J Med Virol 2010; 82: 799-805
• 14 Faber MS, Wenzel JJ, Jilg W et al. Hepatitis E virus seroprevalence among adults, Germany. Emerg Infect Dis 2012; 18: 1654-1657
• 15 Zhu FC, Zhang J, Zhang XF et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010; 376: 895-902
• 16 Rein DB, Stevens GA, Theaker J et al. The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology 2012; 55: 988-997
• 17 Pischke S, Gisa A, Suneetha PV et al. Increased HEV seroprevalence in patients with autoimmune hepatitis. PloS one 2014; 9: e85330
• 18 Baruah B, Bose PD, Ray C et al. Role of genetic alteration in mthfr gene and homocysteine levels as critical factors influencing HEV related pregnancy outcome. J Hepatol 2012; 56: 32-S33
• 19 Mishra N, Arankalle VA. Association of polymorphisms in the promoter regions of TNF-alpha (-308) with susceptibility to hepatitis E virus and TNF-alpha (-1031) and IFN-gamma (+874) genes with clinical outcome of hepatitis E infection in India. J Hepatol 2011; 55: 1227-1234
• 20 Kamar N, Rostaing L, Legrand-Abravanel F et al. How should hepatitis E virus infection be defined in organ-transplant recipients?. Am J Transplant 2013; 13: 1935-1936
• 21 Suneetha PV, Pischke S, Schlaphoff V et al. Hepatitis E virus (HEV)-specific T-cell responses are associated with control of HEV infection. Hepatology 2012; 55: 695-708
• 22 Geng Y, Zhang H, Huang W et al. Persistent hepatitis E virus genotype 4 infection in a child with acute lymphoblastic leukemia. Hepat Mon 2014; 14: e15618
• 23 Dalton HR, Bendall RP, Keane FE et al. Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med 2009; 361: 1025-1027
• 24 Höner zuSiederdissen C, Pischke S, Schlue J et al. Chronic HEV infection beyond transplantation or HIV infection. Hepatology 2013; [Epub ahead of print]
• 25 Kamar N, Bendall RP, Peron JM et al. Hepatitis E virus and neurologic disorders. Emerg Infect Dis 2011; 17: 173-179
• 26 Kamar N, Weclawiak H, Guilbeau-Frugier C et al. Hepatitis E virus and the kidney in solid-organ transplant patients. Transplantation 2012; 93: 617-623
• 27 van den Berg B, van der Eijk AA, Pas SD et al. Guillain-Barré syndrome associated with preceding hepatitis E virus infection. Neurology 2014; 82: 491-497
• 28 Geurtsvankessel CH, Islam Z, Mohammad QD et al. Hepatitis E and Guillain-Barre syndrome. Clin Infect Dis 2013; 57: 1369-1370
• 29 van Eijk JJ, Madden RG, van der Eijk AA et al. Neuralgic amyotrophy and hepatitis E virus infection. Neurology 2014; 82: 498-503
• 30 Bhagat S, Wadhawan M, Sud R et al. Hepatitis viruses causing pancreatitis and hepatitis: a case series and review of literature. Pancreas 2008; 36: 424-427
• 31 Baylis SA, Blumel J, Mizusawa S et al. World Health Organization International Standard to harmonize assays for detection of hepatitis E virus RNA. Emerg Infect Dis 2013; 19: 729-735
• 32 Emerson SU, Arankalle VA, Purcell RH. Thermal stability of hepatitis E virus. J Infect Dis 2005; 192: 930-933
• 33 Pischke S, Stiefel P, Franz B et al. Chronic hepatitis E in heart transplant recipients. Am J Transplant 2012; 12: 3128-3133
• 34 Wang Y, Zhou X, Debing Y et al. Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus. Gastroenterology 2014; 146: 1775-1783
• 35 Haagsma E, Riezebos-Brilman A, Van den Berg AP et al. Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha-2b. Liver Transpl 2010; 16: 474-777
• 36 Kamar N, Rostaing L, Abravanel F et al. Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation. Clin Infect Dis 2010; 50: e30-33